WO2023186997 - MARKERS FOR PROGRESSION OF INFLAMMATORY LIVER DISEASE
National phase entry:
Publication Number
WO/2023/186997
Publication Date
05.10.2023
International Application No.
PCT/EP2023/058171
International Filing Date
29.03.2023
Title **
[English]
MARKERS FOR PROGRESSION OF INFLAMMATORY LIVER DISEASE
[French]
MARQUEURS POUR LA PROGRESSION D'UNE MALADIE HÉPATIQUE INFLAMMATOIRE
Applicants **
RANDOX LABORATORIES LTD
55 The Diamond Road
Crumlin Antrim BT29 4QY, GB
Inventors
LAMONT, John
55 The Diamond Road
Crumlin Antrim BT29 4QY, GB
FITZGERALD, Peter
55 The Diamond Road
Crumlin Antrim BT29 4QY, GB
RUDDOCK, Mark
55 The Diamond Road
Crumlin Antrim BT29 4QY, GB
WATT, Joanne
55 The Diamond Road
Crumlin Antrim BT29 4QY, GB
Priority Data
2204413.5
29.03.2022
GB
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 988 | |
| EPO | Filing, Examination | 4635 | |
| Japan | Filing | 594 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 2710 |
Total: 9502 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The current invention provides biomarkers and combinations thereof for the diagnosis and prognosis of inflammatory liver disease. Methods include the biomarkers suppression of tumorigenicity 2 receptor (ST2), interleukin 6 (IL-6), interleukin 8 (IL-8), tumour necrosis factor alpha (TNFα) and Procollagen III N-terminal peptide (P3NP).[French]
La présente invention concerne des biomarqueurs et des combinaisons de ceux-ci pour le diagnostic et le pronostic d'une maladie hépatique inflammatoire. Les procédés comprennent la suppression de biomarqueurs du récepteur de tumorigénicité 2 (ST2), de l'interleukine 6 (IL-6), de l'interleukine 8 (IL-8), du facteur de nécrose tumorale alpha (TNFα) et du peptide N-terminal de procollagène III (P3NP).